Stock Market Update - February 23, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. ACLX - Arcellx, Inc.
Price: $113.75 | Change: +77.43% ($49.64)
ACLX saw an impressive 77.43% gain recently, largely propelled by the announcement that biotech giant Gilead Sciences plans to acquire Arcellx, Inc. This definitive merger agreement values Arcellx at approximately $7.8 billion, sending its stock soaring.
Gilead's offer of $115 per share in cash, along with a contingent value right, represents a substantial 68% premium over Arcellx's recent average share price. The main driver for this deal is Arcellx's promising lead product, anito-cel, a CAR T-cell therapy targeting a type of blood cancer. Adding to the appeal, the FDA has already accepted the application for anito-cel, signaling a potential approval later this year and giving Gilead full control over its future development.
2. TIRX - Tian Ruixiang Holdings Ltd
Price: $0.076 | Change: +72.73% ($0.032)
TIRX saw an impressive 72.73% gain recently. This surge follows a series of ambitious strategic announcements by Tian Ruixiang Holdings Ltd., signaling a significant pivot into artificial intelligence, cryptocurrency, and traditional finance. A major catalyst was a February 3rd deal where a prominent digital asset investor injected 15,000 Bitcoins (valued at $1.5 billion) in exchange for equity, forging a deep strategic partnership for AI and crypto innovation.
Building on this, TIRX unveiled plans to establish a government-backed stablecoin presence across Southeast Asia, leveraging its new Bitcoin reserves, and simultaneously acquire a fully licensed Australian bank with $200 billion in assets. Most recently, discussions are in final stages for a merger with a leading Asia-Pacific InsurTech company, positioning TIRX as its exclusive platform for U.S. capital markets. This aggressive diversification strategy, merging innovative crypto solutions with established financial sectors, has clearly captured investor excitement.
3. SGN - Signing Day Sports, Inc.
Price: $0.8445 | Change: +62.47% ($0.3247)
SGN experienced an impressive 62.47% gain, primarily fueled by significant advancements in its merger with BlockchAIn Digital Infrastructure, Inc. This business combination, first announced in May 2025, achieved a key milestone when the U.S. SEC declared the merger-related Registration Statement effective on January 30, 2026. This crucial regulatory approval cleared a significant hurdle for the transaction.
Investor confidence further increased when Signing Day Sports announced on February 20, 2026, the exchange ratio for the merger. Signing Day Sports stockholders are set to receive common shares of BlockchAIn, securing at least 8.5% ownership of the combined entity. A special shareholder meeting is scheduled for March 13, 2026, for stockholders to vote on the approval, with the merger anticipated to close in February or March 2026.
What makes this particularly interesting is the combined company's future positioning in the rapidly growing AI infrastructure market, expected to trade under the new ticker AIB. BlockchAIn Digital Infrastructure itself projected strong fundamentals, including $22.9 million in revenue and $5.7 million in net income in 2024, signaling a focused entry into a high-growth sector.
4. KLTO - Klotho Neurosciences, Inc.
Price: $0.41 | Change: +62.25% ($0.1573)
KLTO recently soared with an impressive 62.25% gain. This significant jump for Klotho Neurosciences, Inc. was largely driven by their announcement of securing patent claims in Australia. These patents specifically cover the composition and use of their human secreted Klotho protein ("s-KL") isoform, which is a core component of their research.
This patent grant is a crucial development, providing valuable intellectual property protection for a key part of their therapeutic strategy. Klotho Neurosciences focuses on developing innovative cell and gene therapies that leverage the "anti-aging" Klotho gene, particularly for challenging neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's.
Adding to the positive market sentiment, the company also recently finalized a reverse stock split. This strategic move aims to help them meet Nasdaq's minimum bid price requirement, which reduces the risk of delisting and could attract broader institutional interest in the future.
5. ALUR - Allurion Technologies Inc.
Price: $1.75 | Change: +60.55% ($0.66)
ALUR saw a massive 60.55% gain after securing crucial FDA approval for its Allurion Gastric Balloon System. The announcement on February 23, 2026, sent the stock soaring, as it paves the way for the company to introduce its innovative, non-surgical weight-loss treatment across the United States.
At the heart of this system is the Allurion Smart Capsule, a groundbreaking solution designed to be swallowed during a brief office visit without requiring surgery or anesthesia. Once in the stomach, it expands to promote satiety for about four months before naturally deflating and passing from the body.
This FDA approval marks a "watershed moment" for Allurion, opening up a significant market opportunity. The company estimates approximately 80 million Americans could benefit from this new option, offering an alternative to traditional bariatric surgery and GLP-1 medications for eligible adults with obesity.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.